psalexa
logo

Hepatocellular Carcinoma Therapeutics Pipeline Analysis

Hepatocellular Carcinoma Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11147
Available Format:

Hepatocellular carcinoma is the liver malignancy that develops in the patients suffering from cirrhosis and chronic liver diseases. The disease is caused by liver diseases including hepatitis B or hepatitis C, cirrhosis, alcohol abuse, obesity, diabetes, iron storage disease and aflatoxin. Some of the common symptoms of hepatocellular carcinoma include, pain, lump in upper belly, bloating, weight loss, loss of appetite, nausea, fatigue and fever are the. According to American Cancer Society, around 40,710 new cases of primary liver cancer and intrahepatic bile duct cancer are expected to be diagnosed in the U.S., in 2017. Hepatocellular carcinoma is also a leading cause of cancer deaths worldwide, accounting for more than 600,000 deaths each year. Celgene Corporation is in the process of developing CC-122 as a signal transduction pathway modulator for the treatment of hepatocellular carcinoma. Some of the companies having a pipeline of hepatocellular carcinoma include Eisai Co., Ltd., Celgene Corporation, and AstraZeneca plc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry